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a similar track record, no valid conclusion can be drawn Peritoneal elimination of
as to the comparative carcinogenicity (or absence thereof)
of other cardiovascular drugs. Therefore, the low-rate homocysteine moieties in
carcinogenicity of diuretic therapy should only serve as
a reminder to us practicing physicians that any drug continuous ambulatory
therapy has its inherent yet often unknown risks.
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